Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ASG-5ME · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | ASG-5ME |
| Name | Type | Description |
|---|---|---|
| ASG-5ME | DRUG | 0.3-3.0 mg/kg IV on Days 1, 8, and 15 of 28-day cycles |
Inclusion Criteria: * Pathologically confirmed metastatic pancreatic adenocarcinoma or pathologically confirmed AGS-5-positive gastric or gastric esophageal junction adenocarcinoma * Measurable disease (at least one nonresectable, non-nodal lesion greater than or equal to 10 mm in longest diameter ...
ASG-5ME is an investigational small molecule being developed for the treatment of gastric neoplasms, a type of stomach cancer. It was studied in a Phase 1 clinical trial that also included patients with pancreatic adenocarcinoma, another form of cancer.
ASG-5ME is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in clinical development and has not been approved by regulatory authorities.
ASG-5ME is in Phase 1 clinical development. A Phase 1 dose escalation trial of the drug has been completed, but it remains investigational and is not yet approved for any use. Further clinical studies would be needed to establish its safety and efficacy.
ASG-5ME has been studied in one clinical trial, identified as NCT01166490, titled 'A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma.' This trial enrolled 51 participants in the United States and has been completed.
ASG-5ME is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial, but it has not received marketing approval from the U.S. Food and Drug Administration or any other regulatory agency.